The JAK/STAT signaling pathway: from bench to clinic
X Hu, J Li, M Fu, X Zhao, W Wang - Signal transduction and targeted …, 2021 - nature.com
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …
significant clinical attention in oncology due to their central role in cancer pathogenesis …
[HTML][HTML] Classification and personalized prognosis in myeloproliferative neoplasms
J Grinfeld, J Nangalia, EJ Baxter… - … England Journal of …, 2018 - Mass Medical Soc
Background Myeloproliferative neoplasms, such as polycythemia vera, essential
thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied …
thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied …
Acute lymphoblastic leukaemia
H Inaba, M Greaves, CG Mullighan - The Lancet, 2013 - thelancet.com
Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks
between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous …
between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous …
Philadelphia chromosome–like acute lymphoblastic leukemia
Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as
BCR-ABL1–like ALL, is a high-risk subset with a gene expression profile that shares …
BCR-ABL1–like ALL, is a high-risk subset with a gene expression profile that shares …
JAKs and STATs in immunity, immunodeficiency, and cancer
JAKs and STATs in Immunity, Immunodeficiency, and Cancer | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …
Skip to main content The New England Journal of Medicine homepage Advanced Search …
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group
SC Reshmi, RC Harvey, KG Roberts… - Blood, The Journal …, 2017 - ashpublications.org
Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk
subtype characterized by genomic alterations that activate cytokine receptor and kinase …
subtype characterized by genomic alterations that activate cytokine receptor and kinase …
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Improved supportive care, more precise risk stratification, and personalized chemotherapy
based on the characteristics of leukemic cells and hosts (eg, pharmacokinetics and …
based on the characteristics of leukemic cells and hosts (eg, pharmacokinetics and …
The molecular regulation of Janus kinase (JAK) activation
The JAK (Janus kinase) family members serve essential roles as the intracellular signalling
effectors of cytokine receptors. This family, comprising JAK1, JAK2, JAK3 and TYK2 (tyrosine …
effectors of cytokine receptors. This family, comprising JAK1, JAK2, JAK3 and TYK2 (tyrosine …
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine
SP Hunger, CG Mullighan - Blood, The Journal of the American …, 2015 - ashpublications.org
Acute lymphoblastic leukemia (ALL) is the commonest childhood tumor and remains a
leading cause of cancer death in the young. In the last decade, microarray and sequencing …
leading cause of cancer death in the young. In the last decade, microarray and sequencing …